← Eichor
Study identifier: NCT06805825 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Condition: Gastrointestinal Stromal Tumors · Small-cell Lung Cancer · Adenoid Cystic Carcinoma  ·  Sponsor: Novelty Nobility, Inc.

PhasePhase 1
Planned participants67
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trial Lead  ·  1 617.870.7173  ·  NN3201@noveltynobility.com

Always discuss trial participation with your own doctor first.

Locations (5)

University of Michigan HospitalsAnn Arbor, Michigan, United StatesRecruiting
Case Comprehensive Cancer CenterCleveland, Ohio, United StatesRecruiting
Oregon Health & Science UniversityPortland, Oregon, United StatesRecruiting
The University of Texas MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting
NEXT VirginiaFairfax, Virginia, United StatesActive Not Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06805825